Information about clinical trials provided solely for education and awareness purposes. Patients should consult their medical doctor for advice and recomendations about specific clinical trials. PHEN does not provide medical advice, or recommendations to patients about clinical trials. The clinical trials highlighted are for those organizations who sponsor and support PHEN education and awareness initiatives.

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance, This randomized clinical trial is studying how well diet works in altering disease progression in patients with prostate cancer on active surveillance. Information	Understanding Clinical Trials, * What is a clinical trial? * Why participate in a clinical trial? * Who can participate in a clinical trial? * What are the benefits and risks of participating in a clinical trial?....And more Information
Entering A Clinical Trial, Is It Right For You?, A Dana-Farber video to assist patients in understanding and making choices about clinical trials. Information	Prostate Cancer Clinical Trials, Information providing the purpose, description, eligibility criteria and status for more than 1700 prostate cancer clinical trials/studies in the United States. Information
National Cancer Institute's list of clinical trials now accepting patients, The list of clinical trials can be refined by location, stage of disease, drug, and other features Information	Introducing Clinical Trials, A PHEN Presentation: Mr. Mark Kennedy An overview of clinical trials emphasizing the importance of African American men participation. Information
TrialX, TrialX is a service to help patients find clinical trials that match their health conditions and connect with investigators conducting trials. Information	PROSPER, A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer Information
SPARTAN, The purpose of this study is to evaluate the efficacy and safety of ARN-509 in adult men with high-risk non-metastatic castration-resistant prostate cancer. Information	ProstAtak™, This study will evaluate the effectiveness of ProstAtak™ immunotherapy to reduce the recurrence of intermediate-high risk localized prostate cancer when used in combination with radiation therapy. Information
Iris Personalized Medicine, A division of Iris International, is dedicated to enabling the advancement of predictive and personalized cancer treatment options. Information	Cyberknife, Prostate cancer clinical trials for the CyberKnife® Robotic Radiosurgery System - a non-invasive alternative to surgery. Information
BN ImmunoTherapeutics, PROSPECT PROSTVAC® is a therapeutic vaccine candidate in Phase 3 clinical development that has the potential to significantly extend the lives of men with advanced prostate cancer. Information	IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen, The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Information
Affinity, Metastatic prostate Cancer The goal of this Phase 3 clinical trial is to test whether adding an experimental drug called custirsen to Jevtana® (cabazitaxel) chemotherapy can help treat metastatic castrate-resistant prostate cancer (mCRPC) Information	PSMA ADC: Metastatic Prostate Cancer Progression After prior Taxane Therapy, Progenics PSMA ADC 1301 - A phase 1 metastatic study of intravenous PSMA ADC in patients with progressive castration-resistant prostate cancer previously treated with two or fewer chemotherapy regimens, one of which includes taxane or a taxane derivative. Information